Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,421 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adaptive resistance to targeted therapies in cancer.
Rosell R, Karachaliou N, Morales-Espinosa D, Costa C, Molina MA, Sansano I, Gasco A, Viteri S, Massuti B, Wei J, González Cao M, Martínez Bueno A. Rosell R, et al. Among authors: costa c. Transl Lung Cancer Res. 2013 Jun;2(3):152-9. doi: 10.3978/j.issn.2218-6751.2012.12.08. Transl Lung Cancer Res. 2013. PMID: 25806228 Free PMC article. Review.
Biomarkers in lung oncology.
Rosell R, Vergnenegre A, Liu B, Cobo M, Massuti B, Wei J, Molina MA, Costa C, Queralt C, Taron M. Rosell R, et al. Among authors: costa c. Pulm Pharmacol Ther. 2010 Dec;23(6):508-14. doi: 10.1016/j.pupt.2010.05.003. Epub 2010 May 13. Pulm Pharmacol Ther. 2010. PMID: 20471486 Review.
Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations.
Rosell R, Molina MA, Costa C, Simonetti S, Gimenez-Capitan A, Bertran-Alamillo J, Mayo C, Moran T, Mendez P, Cardenal F, Isla D, Provencio M, Cobo M, Insa A, Garcia-Campelo R, Reguart N, Majem M, Viteri S, Carcereny E, Porta R, Massuti B, Queralt C, de Aguirre I, Sanchez JM, Sanchez-Ronco M, Mate JL, Ariza A, Benlloch S, Sanchez JJ, Bivona TG, Sawyers CL, Taron M. Rosell R, et al. Among authors: costa c. Clin Cancer Res. 2011 Mar 1;17(5):1160-8. doi: 10.1158/1078-0432.CCR-10-2158. Epub 2011 Jan 13. Clin Cancer Res. 2011. PMID: 21233402
mRNA expression levels and genetic status of genes involved in the EGFR and NF-κB pathways in metastatic non-small-cell lung cancer patients.
Santarpia M, Magri I, Sanchez-Ronco M, Costa C, Molina-Vila MA, Gimenez-Capitan A, Bertran-Alamillo J, Mayo C, Benlloch S, Viteri S, Gasco A, Mederos N, Carcereny E, Taron M, Rosell R. Santarpia M, et al. Among authors: costa c. J Transl Med. 2011 Sep 27;9:163. doi: 10.1186/1479-5876-9-163. J Transl Med. 2011. PMID: 21951562 Free PMC article.
KRAS mutations in lung cancer.
Karachaliou N, Mayo C, Costa C, Magrí I, Gimenez-Capitan A, Molina-Vila MA, Rosell R. Karachaliou N, et al. Among authors: costa c. Clin Lung Cancer. 2013 May;14(3):205-14. doi: 10.1016/j.cllc.2012.09.007. Epub 2012 Nov 1. Clin Lung Cancer. 2013. PMID: 23122493 Review.
BRCA1, LMO4, and CtIP mRNA expression in erlotinib-treated non-small-cell lung cancer patients with EGFR mutations.
Karachaliou N, Costa C, Gimenez-Capitan A, Molina-Vila MA, Bertran-Alamillo J, Mayo C, Massuti B, Majem M, Carcereny E, Moran T, Sanchez JJ, Viteri S, Gasco A, Wannesson L, Souglakos J, Jimeno J, Rosell R; Spanish Lung Cancer Group. Karachaliou N, et al. Among authors: costa c. J Thorac Oncol. 2013 Mar;8(3):295-300. doi: 10.1097/JTO.0b013e31827db621. J Thorac Oncol. 2013. PMID: 23407556 Free article.
The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial.
Costa C, Molina MA, Drozdowskyj A, Giménez-Capitán A, Bertran-Alamillo J, Karachaliou N, Gervais R, Massuti B, Wei J, Moran T, Majem M, Felip E, Carcereny E, Garcia-Campelo R, Viteri S, Taron M, Ono M, Giannikopoulos P, Bivona T, Rosell R. Costa C, et al. Clin Cancer Res. 2014 Apr 1;20(7):2001-10. doi: 10.1158/1078-0432.CCR-13-2233. Epub 2014 Feb 3. Clin Cancer Res. 2014. PMID: 24493829 Clinical Trial.
ALK and ROS1 as a joint target for the treatment of lung cancer: a review.
Puig de la Bellacasa R, Karachaliou N, Estrada-Tejedor R, Teixidó J, Costa C, Borrell JI. Puig de la Bellacasa R, et al. Among authors: costa c. Transl Lung Cancer Res. 2013 Apr;2(2):72-86. doi: 10.3978/j.issn.2218-6751.2013.03.1. Transl Lung Cancer Res. 2013. PMID: 25806218 Free PMC article. Review.
4,421 results